- Home
- GSL vs SNY Comparison
GSL vs SNY Comparison
Compare GSL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- SNY
- Stock Information
- Founded
- GSL 2007
- SNY 1994
- Country
- GSL Greece
- SNY France
- Employees
- GSL N/A
- SNY N/A
- Industry
- GSL Marine Transportation
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- SNY Health Care
- Exchange
- GSL Nasdaq
- SNY Nasdaq
- Market Cap
- GSL 1.1B
- SNY 113.4B
- IPO Year
- GSL 2006
- SNY N/A
- Fundamental
- Price
- GSL $31.92
- SNY $47.03
- Analyst Decision
- GSL Strong Buy
- SNY Buy
- Analyst Count
- GSL 1
- SNY 4
- Target Price
- GSL $33.00
- SNY $61.50
- AVG Volume (30 Days)
- GSL 317.1K
- SNY 2.8M
- Earning Date
- GSL 11-10-2025
- SNY 10-24-2025
- Dividend Yield
- GSL 6.58%
- SNY 3.40%
- EPS Growth
- GSL 19.05
- SNY 118.56
- EPS
- GSL 10.76
- SNY 8.65
- Revenue
- GSL $730,277,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- GSL $5.44
- SNY $2.01
- Revenue Next Year
- GSL N/A
- SNY $6.82
- P/E Ratio
- GSL $2.97
- SNY $10.74
- Revenue Growth
- GSL 4.04
- SNY 15.65
- 52 Week Low
- GSL $17.73
- SNY $44.73
- 52 Week High
- GSL $32.45
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- GSL 69.71
- SNY 42.55
- Support Level
- GSL $31.00
- SNY $46.79
- Resistance Level
- GSL $31.78
- SNY $47.69
- Average True Range (ATR)
- GSL 0.51
- SNY 0.71
- MACD
- GSL 0.09
- SNY -0.27
- Stochastic Oscillator
- GSL 83.28
- SNY 32.62
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.